Dr. Borrello is an associate professor of oncology at the Johns Hopkins University School of Medicine and director of the Cell Therapy and cGMP Biologics Core for the Johns Hopkins Kimmel Cancer Center. He is a member of the Hematologic Malignancies and Bone Marrow Translational Program.
Dr. Borrello's clinical research interest is in developing immune based therapies for the treatment of multiple myeloma. His laboratory interests have focused on the development of a novel approach of adoptive T cell therapy utilizing marrow infiltrating lymphocytes (MILs) as a more tumor specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins, and he is currently exploring this approach in other diseases including non-hematologic malignancies. Dr. Borrello is also examining strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines.
Dr. Borrello received his medical degree from the Medical College of Virginia, did his residency at the University of Chicaco and fellowship at Johns Hopkins.